Babies' DNA affects mothers' risk of pre-eclampsia in pregnancy
Strong evidence found for a number of genetic variations near to the FLT1 gene being linked to increased risk of pre-eclampsia
A major new international study has revealed for the first time that some features in a baby’s DNA can increase the risk of its mother developing pre-eclampsia – a potentially dangerous condition in pregnancy.
These results from the InterPregGen study are published in Nature Genetics. The work was carried out by genetics experts from the UK, Nordic countries and Central Asia and is the first to show an effect of DNA from the fetus on the health of its mother.
Pre-eclampsia affects up to 5 per cent of pregnancies and is first suspected when a woman is found to have high blood pressure, usually in the second half of pregnancy. The condition can cause serious complications including fits, stroke, liver and blood problems and in some cases the death of mother and baby.
The five-year study involved teams from the UK, Iceland, Finland, Norway, Kazakhstan and Uzbekistan. They studied the genetic make-up of 4,380 babies born from pre-eclamptic pregnancies and compared their DNA with over 300,000 healthy individuals.
Dr Linda Morgan, from the University of Nottingham’s School of Life Sciences, coordinated the five-year study, which included DNA samples contributed from Iceland, Norway and Finland as well as from more than 20 universities and maternity units in the UK.
“For many years midwives and obstetricians have known that a woman is more likely to develop pre-eclampsia if her mother or sister had the disorder. More recently research has shown that the condition also runs in the families of men who father pre-eclamptic pregnancies. We knew that faulty formation of the placenta is often found in pre-eclampsia. As it is the baby’s genes that produce the placenta we set out to see if we could find a link between the baby’s DNA and the condition. We found there were indeed some features in a baby’s DNA that can increase the risk of pre-eclampsia.”
Dr Linda Morgan University of Nottingham’s School of Life Sciences, who coordinated the InterPregGen study
Laboratory and statistical analysis performed at the Wellcome Trust Sanger Institute (UK) and deCODE Genetics (Iceland) pinpointed the location in the baby’s DNA that increases risk of pre-eclampsia. This location was confirmed by other InterPregGen members to fit hand-in-glove with other medical information about pre-eclampsia.
“Pre-eclampsia has been recognized since ancient Egypt and Greece as being a danger to the lives of mothers and babies. This first piece of the genetic jigsaw holds substantial promise for unlocking some of the mystery of how pre-eclampsia is caused. Our finding may also enable better prediction of mothers who will become pre-eclamptic when combined clinical information and with other pieces of the genetic jigsaw that will also surely be discovered in the next few years.”
Dr Ralph McGinnis Who led the analysis at the Sanger Institute
The baby’s DNA comes from both its mother’s and its father’s genes – in keeping with the inherited risk of pre-eclampsia. The DNA changes associated with pre-eclampsia are common – more than 50 per cent of people carry this sequence in their DNA so the inherited changes are not sufficient in themselves to cause disease, but they do increase the risk of pre-eclampsia.
The research found DNA variations close to the FLT1 gene that makes a protein called sFlt-1 with significant differences between the babies born from pre-eclamptic pregnancies and the control group.
“It is striking that we have found strong evidence for not just a single associated genetic variant but for multiple independently associated variants in the vicinity of the FLT1 gene. This indicates that this region of the genome is likely to be fruitful territory for further investigation.”
Dr Nicholas Williams A lead author on the paper from the Sanger Institute
At high levels sFlt-1 released from the placenta into the mother’s bloodstream can cause damage to her blood vessels, leading to high blood pressure and damage to her kidneys, liver and brain – all features of pre-eclampsia. If a baby carried these genetic variants it increased the risk of that pregnancy developing pre-eclampsia.
“Because pre-eclampsia has its origins in the very early stages of pregnancy, during the formation of the placenta, research into the causes and processes of the disease has always been challenging. Now modern genome wide screening and its data analysis allows us to look for clues in the mother’s, father’s and their baby’s DNA. We believe the new insights from this study could form the basis for more effective prevention and treatment of pre-eclampsia in the future, and improve the outcome of pregnancy for mother and child.”
Dr Linda Morgan University of Nottingham’s School of Life Sciences
DNA from a further 4,220 babies from pre-eclamptic pregnancies in Kazakhstan and Uzbekistan is currently being analysed in an extended study to see if the same variations occur near the gene encoding sFlt-1.
If you need help or have any queries, please contact us using the details below.
Notes to Editor
The research was funded by a €6 million grant from the European Commission, supported by Wellcome, the UK Medical Research Council, and the European Research Council. Please see paper for full list of funders.
The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in China and Malaysia, as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among graduate employers and the winner of ‘Outstanding Support for Early Career Researchers’ at the Times Higher Education Awards 2015. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and 8th in the UK by research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for three years running, according to Greenmetrics Ranking of World Universities.
Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future.
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.
8 Jul 2020
Launch of virtual Sanger Seminar series
Join us for a new series of virtual seminars, open to all, which will present the latest research from the Sanger ...
7 Jul 2020
Drug screens and CRISPR combine to help make better cancer drugs
Improved understanding of the biological mechanisms underpinning drug response will enable faster, more efficient drug development